- Home
- ACET vs LPTH Comparison
ACET vs LPTH Comparison
Compare ACET & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- LPTH
- Stock Information
- Founded
- ACET 1947
- LPTH 1985
- Country
- ACET United States
- LPTH United States
- Employees
- ACET N/A
- LPTH N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- LPTH Semiconductors
- Sector
- ACET Health Care
- LPTH Technology
- Exchange
- ACET Nasdaq
- LPTH Nasdaq
- Market Cap
- ACET 70.3M
- LPTH 81.1M
- IPO Year
- ACET N/A
- LPTH 1996
- Fundamental
- Price
- ACET $0.66
- LPTH $1.77
- Analyst Decision
- ACET Buy
- LPTH Strong Buy
- Analyst Count
- ACET 6
- LPTH 3
- Target Price
- ACET $6.00
- LPTH $4.67
- AVG Volume (30 Days)
- ACET 312.0K
- LPTH 107.1K
- Earning Date
- ACET 03-06-2025
- LPTH 05-08-2025
- Dividend Yield
- ACET N/A
- LPTH N/A
- EPS Growth
- ACET N/A
- LPTH N/A
- EPS
- ACET N/A
- LPTH N/A
- Revenue
- ACET N/A
- LPTH $32,158,517.00
- Revenue This Year
- ACET N/A
- LPTH $16.90
- Revenue Next Year
- ACET N/A
- LPTH $52.77
- P/E Ratio
- ACET N/A
- LPTH N/A
- Revenue Growth
- ACET N/A
- LPTH N/A
- 52 Week Low
- ACET $0.67
- LPTH $1.04
- 52 Week High
- ACET $2.40
- LPTH $4.42
- Technical
- Relative Strength Index (RSI)
- ACET 34.86
- LPTH 30.50
- Support Level
- ACET $0.74
- LPTH $2.03
- Resistance Level
- ACET $0.91
- LPTH $2.24
- Average True Range (ATR)
- ACET 0.06
- LPTH 0.17
- MACD
- ACET -0.01
- LPTH -0.01
- Stochastic Oscillator
- ACET 4.82
- LPTH 10.96
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.